Lilly Migraine Treatment Moves Forward

Posted: Updated:
Lilly plans to present trial results at scientific meetings and publications over the next year. Lilly plans to present trial results at scientific meetings and publications over the next year.
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says its second Phase 3 study of an oral migraine treatment has yielded positive results. Lilly says as a result of the positive outcome for lasmiditan, the company plans to submit a New Drug Application with the U.S. Food and Drug Administration in the second half of 2018.

Lilly says the treatment met its primary endpoint in the SPARTAN study, which showed that a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo after two hours of taking the first dose. The drug also met is secondary endpoint, which showed that a "statistically significantly greater percentage" of patients were free of their most bothersome symptoms, such as nausea and sensitivity to sound or light.

"Lasmiditan represents the first significant innovation in the acute treatment of migraine in more than 20 years, and could provide a much-needed new treatment option for the 36 million Americans living with migraine," said Christi Shaw, president of Lilly Bio-Medicines. "We are thrilled with these topline lasmiditan results, which add to more than 25 years of Lilly's research and development of migraine therapies."

The company plans to present data from both studies at scientific meetings and submit results to peer-reviewed journals over the next year. The company has already begun another Phase 3 study, known as GLADIATOR, to evaluate the long-term safety of the drug for the acute treatment of migraine.

The treatment was originally discovered by Lilly in 2005 and later sold the rights to lasmiditan to Massachusetts-based CoLucid Pharmaceuticals Inc, which continued to develop the drug. Lilly recently-completed a $960 million acquisition of CoLucid, a deal which was profiled by Inside INdiana Business Reporter Kylie Veleta in our Life Sciences INdiana e-newsletter.

  • Perspectives

    • The Power of Partnerships

      You can't go it alone in tech. All technology companies, regardless of their segment, live in an ecosystem comprised of organisms of varying complexity. More mature companies in established categories can function at the top of the food chain, consuming smaller companies through acquisition, but startups are seldom if ever in a position to gain dominance through acquisition. It’s vital for the success of a startup to be able to play well with others...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Liberty Mutual Plans 400 New Carmel Jobs

      Boston-based Liberty Mutual Group Inc. is planning to add up to 400 Carmel jobs as part of a $14 million expansion plan. The insurance company has a global presence and currently employs 1,430 in central Indiana. The Indiana Economic Development Corp. says the new jobs, expected to be created by 2021, will pay more than the state and Hamilton County average wages. Plans call for Liberty Mutual to lease...

    • Vincennes Woman Sentenced For Tax Fraud

      U.S. District Judge Richard Young has sentenced a Vincennes woman to four years in prison on tax fraud charges. U.S. Attorney Josh Minkler's office says Deborah Richards pleaded guilty to preparing more than 350 false tax returns between 2014 and 2017. 

    • Soybean Alliance Chair Appointed to National Board

      The chairman of the Indiana Soybean Alliance Board of Directors has been named to a national board. Tom Griffiths of Kendallville is one of 19 new members appointed to the United Soybean Board by U.S. Secretary of Agriculture Sonny Perdue. 

    • Opioid Withdrawal Treatment Lands FDA Clearance

      The U.S. Food and Drug Administration has given clearance for a medical device developed in Indiana to help treat symptoms of opioid withdrawal. The device, known as the NSS-2 BRIDGE, was created by Innovative Health Solutions Inc. in Versailles.

    • FedEx Plans to Pump $170M Into Indy Hub

      FedEx Corp. (NYSE: FDX) is planning a $170 million investment in its hub at Indianapolis International Airport. In a tax abatement request introduced Monday evening to the City-County Council in Indianapolis, the company says plans call for more than two dozen additional full-time and nearly 180 part-time positions. FedEx says the installation of new package-handling equipment would also help retain some 730 full-timers and 3,200 part-timers.